Cargando…
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60–65% of patients can be cured by chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, patients...
Autores principales: | Frontzek, Fabian, Karsten, Imke, Schmitz, Norbert, Lenz, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243592/ https://www.ncbi.nlm.nih.gov/pubmed/35785244 http://dx.doi.org/10.1177/20406207221103321 |
Ejemplares similares
-
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
por: Thieblemont, Catherine, et al.
Publicado: (2023) -
Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014) -
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020) -
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell
Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020) -
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)